Reported about 13 hours ago
BMO Capital Markets has reduced its price target for Novo Nordisk from $156 to $105 per share following disappointing results from its weight-loss drug CagriSema, which underperformed in expected weight loss. Analyst Evan Seigerman noted that Novo is struggling to compete against more effective drugs like Tirzepatide and upcoming releases from competitors, indicating that the company's momentum may be waning.
Source: YAHOO